Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503119-40-00

Acronym

DACTOS

Enrollment

Registered

2025-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis (PsA)

Brief summary

1) To assess the efficacy of ixekizumab monotherapy versus MTX monotherapy in PsA dactylitis 2) To evaluate the degree of response by using the DACTOS score and the change of each sonographic detected elementary lesion of dactylitis in PsA participants

Interventions

DRUGTaltz 80 mg solution for injection in pre-filled syringe

DRUGMetother 50 mg/ml soluzione iniettabile in siringa pre-riempita.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1) To assess the efficacy of ixekizumab monotherapy versus MTX monotherapy in PsA dactylitis 2) To evaluate the degree of response by using the DACTOS score and the change of each sonographic detected elementary lesion of dactylitis in PsA participants	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026